Literature DB >> 2675998

Symmetric group sequential test designs.

S S Emerson1, T R Fleming.   

Abstract

In Phase III clinical trials, ethical considerations often demand interim analyses in order that the better treatment be made available to all patients as soon as possible. Group sequential test designs that do not treat the hypotheses symmetrically may not fully address this concern since early termination of the study may be easier under one of the hypotheses. We present a one-parameter family of symmetric one-sided group sequential designs that are nearly fully efficient in terms of the average sample number. The symmetric tests are then extended to a two-sided hypothesis test. These symmetric two-sided group sequential tests are found to have improved overall efficiency when compared to the tests proposed by Pocock (1977, Biometrika 64, 191-199) and O'Brien and Fleming (1979, Biometrics 35, 549-556). Tables of critical values for both one-sided and two-sided symmetric designs are provided, thus allowing easy determination of sample sizes and stopping boundaries for a group sequential test. Approximate tests based on these designs are proposed for use when the number and timing of analyses are random.

Entities:  

Mesh:

Year:  1989        PMID: 2675998

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  14 in total

1.  Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples.

Authors:  Ying Qing Chen; Benoit Masse; Lei Wang; San-San Ou; Xin Li; Deborah Donnell; Marybeth McCauley; Theresa Gamble; Heather J Ribauldo; Myron S Cohen; Thomas R Fleming
Journal:  Contemp Clin Trials       Date:  2012-07-16       Impact factor: 2.226

2.  Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.

Authors:  Marianne Sponer Muhlebach; Valeria Beckett; Elena Popowitch; Melissa B Miller; Arthur Baines; Nicole Mayer-Hamblett; Edith T Zemanick; Wynton C Hoover; Jill M VanDalfsen; Preston Campbell; Christopher H Goss
Journal:  Thorax       Date:  2016-11-15       Impact factor: 9.139

3.  Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings.

Authors:  Sarah C Emerson; Kyle D Rudser; Scott S Emerson
Journal:  Stat Med       Date:  2010-12-29       Impact factor: 2.373

4.  Clinical trials: discerning hype from substance.

Authors:  Thomas R Fleming
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

5.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

6.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

7.  The utility of Bayesian predictive probabilities for interim monitoring of clinical trials.

Authors:  Benjamin R Saville; Jason T Connor; Gregory D Ayers; JoAnn Alvarez
Journal:  Clin Trials       Date:  2014-05-28       Impact factor: 2.486

8.  Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.

Authors:  Joseph S Koopmeiners; Ziding Feng
Journal:  Stat Med       Date:  2015-11-04       Impact factor: 2.373

9.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10

10.  A flexible futility monitoring method with time-varying conditional power boundary.

Authors:  William R Clarke
Journal:  Clin Trials       Date:  2010-04-27       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.